Liza G G van Lent1, Lea J Jabbarian2, Jelle van Gurp3, Jeroen Hasselaar4, Martijn P Lolkema5, Julia C M van Weert6, Carin C D van der Rijt5, Maja J A de Jonge5. 1. Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: l.vanlent@erasmusmc.nl. 2. Department of Psychiatry, Erasmus MC, Rotterdam, the Netherlands. 3. Department of IQ Healthcare, Radboud University Medical Centre, Nijmegen, the Netherlands. 4. Department of Anaesthesiology, Pain & Palliative Medicine, Radboud University Medical Centre, Nijmegen, the Netherlands. 5. Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. 6. Department of Communication Science, Amsterdam School of Communication Research (ASCoR) and University of Amsterdam, Amsterdam, the Netherlands.
Abstract
BACKGROUND: For many patients with advanced cancer, the decision whether to participate in early phase clinical trials or not is complex. The decision-making process requires an in-depth discussion of patient values. We therefore aimed to synthesize and describe patient values that may affect early phase clinical trial participation. METHODS: We conducted a systematic search in seven electronic databases on patient values in relation to patients' decisions to participate in early phase clinical cancer trials. RESULTS: From 3072 retrieved articles, eleven quantitative and five qualitative studies fulfilled our inclusion criteria. We extracted ten patient values that can contribute to patients' decisions. Overall, patients who seek trial participation usually report hope, trust, quantity of life, altruism, perseverance, faith and/or risk tolerance as important values. Quality of life and humanity are main values of patients who refuse trial participation. Autonomy and social adherence can be reported by both trial seekers or refusers, dependent upon how they are manifested in a patient. CONCLUSIONS: We identified patient values that frequently play a role in the decision-making process. In the setting of discussing early phase clinical trial participation with patients, healthcare professionals need to be aware of these values. This analysis supports the importance of individual exploration of values. Patients that become aware of their values, e.g. by means of interventions focused on clarifying their values, could feel more empowered to choose. Subsequently, healthcare professionals could improve their support in a patients' decision-making process and reduce the chance of decisional conflict.
BACKGROUND: For many patients with advanced cancer, the decision whether to participate in early phase clinical trials or not is complex. The decision-making process requires an in-depth discussion of patient values. We therefore aimed to synthesize and describe patient values that may affect early phase clinical trial participation. METHODS: We conducted a systematic search in seven electronic databases on patient values in relation to patients' decisions to participate in early phase clinical cancer trials. RESULTS: From 3072 retrieved articles, eleven quantitative and five qualitative studies fulfilled our inclusion criteria. We extracted ten patient values that can contribute to patients' decisions. Overall, patients who seek trial participation usually report hope, trust, quantity of life, altruism, perseverance, faith and/or risk tolerance as important values. Quality of life and humanity are main values of patients who refuse trial participation. Autonomy and social adherence can be reported by both trial seekers or refusers, dependent upon how they are manifested in a patient. CONCLUSIONS: We identified patient values that frequently play a role in the decision-making process. In the setting of discussing early phase clinical trial participation with patients, healthcare professionals need to be aware of these values. This analysis supports the importance of individual exploration of values. Patients that become aware of their values, e.g. by means of interventions focused on clarifying their values, could feel more empowered to choose. Subsequently, healthcare professionals could improve their support in a patients' decision-making process and reduce the chance of decisional conflict.
Authors: Jelle L P van Gurp; Liza G G van Lent; Nicole Stoel; Carin C D van der Rijt; Maja J A de Jonge; Saskia M Pulleman; Julia C M van Weert; Jeroen Hasselaar Journal: Support Care Cancer Date: 2022-06-08 Impact factor: 3.359
Authors: Liza G G van Lent; Maja J A de Jonge; Mirte van der Ham; Marjolein van Mil; Eelke H Gort; Jeroen Hasselaar; Esther Oomen-de Hoop; Carin C D van der Rijt; Julia C M van Weert; Martijn P Lolkema Journal: Cancers (Basel) Date: 2022-03-15 Impact factor: 6.639